$126.20
+0.56%
N/A+$0.70
보건 의료
의료 - 기기
NYSE
활발히 거래 중
Integer Holdings Corporation은 미국, 푸에르토리코, 코스타리카 및 기타 국제 지역 전역에서 사업을 운영하며, 위탁 의료기기 제조 분야의 글로벌 리더로 기능합니다. 회사는 사업을 ...
P
Payman Khales
Integer Holdings Corporation
재임 기간 1y핵심 인물 리스크: Low
Payman Khales is an operational-focused leader well-suited to the stability and precision required in the CDMO sector. His successful transition suggests a disciplined leadership style, though investors will look for...
핵심 위험
•Execution risk in a high-demand CDMO environment
•Regulatory hurdles typical of medtech sector
•Limited public track record as CEO
핵심 순풍
•Industry trend favoring medical outsourcing
•Strong operational foundation
•Clear strategic focus on innovation
P
Payman Khales
Integer Holdings Corporation (ITGR) · NYSE
재임 기간 1 년비창업자 CEO핵심 인물 리스크: Low
출신 배경
Payman Khales ascended to the CEO role after serving as Chief Operating Officer, following a planned succession of his predecessor, Joseph Dziedzic.
첫 기회: Served as Chief Operating Officer at Integer Holdings Corporation, overseeing both major business units (Cardio & Vascular and CRM & Neuromodulation) prior to his appointment as CEO.
CEO가 되기까지: Khales was appointed as President and CEO in October 2025 as part of a multi-year planned succession. His deep operational experience within the company, gained while leading the business units as COO, positioned him as the clear successor to Joe Dziedzic.
초기 비전: Focus on delivering innovative, cost-effective solutions to enable customers' medical device success.
Payman Khales took the helm of Integer Holdings Corporation in October 2025, succeeding longtime CEO Joseph Dziedzic. His transition was the culmination of a deliberate succession process, leveraging his internal operational experience as COO, where he managed the company's core business units and refined its market strategy.
internal promotionoperational leadershipsuccession
투자 관점
Payman Khales is an operational-focused leader well-suited to the stability and precision required in the CDMO sector. His successful transition suggests a disciplined leadership style, though investors will look for...
긍정 요인
Industry trend favoring medical outsourcing
Strong operational foundation
Clear strategic focus on innovation
핵심 리스크
Execution risk in a high-demand CDMO environment
Regulatory hurdles typical of medtech sector
Limited public track record as CEO
경력
Career built on deep operational roles within the medical device contract manufacturing space.
Integer Holdings Corporation
이니셔티브: President and CEO
기간: 2025–Present
사건: Led organizational transition and continuity; spearheading current innovation strategies.
Integer Holdings Corporation
이니셔티브: Chief Operating Officer
기간: Pre-2025
사건: Managed core business units Cardio & Vascular and CRM & Neuromodulation.
medical manufacturingcdmooperations
회사 성과
The company remains a significant player in the CDMO space, currently focused on growth strategies initiated under prior leadership.
매출: Maintaining steady growth as a leading medical device contract development and manufacturing organization.
수익성: Focus on operational efficiency and cost-effective solutions as core to the current margin strategy.
주가: Stock performance continues to reflect market sentiment around medical technology outsourcing trends.
•Smooth executive transition from predecessor
cdmomedtech
경영 역량
Prioritizes operational discipline and customer-centric innovation.
스타일: Operational operator
As a former COO, Khales brings a hands-on approach to organizational design and execution. He focuses heavily on integrating business units to improve the delivery of innovative, cost-effective solutions to customers. His leadership emphasizes cultural continuity, building on the foundation established by his predecessor.
operationalcustomer-centricexecution
자본 배분
Maintains a disciplined approach to capital allocation focused on sustaining the CDMO business model.
Focus on efficiency and delivering cost-effective manufacturing solutions to drive margins.
Khales continues to manage Integer's capital allocation with an emphasis on R&D for manufacturing innovation and infrastructure investment to support customer needs. His strategy is deeply integrated with the operational requirements of a global medical device CDMO.
cost efficiencycapital discipline
자금 조달 및 파이낸싱
Relies on established financial infrastructure of a mature public CDMO.
희석: minimal
The focus is on maintaining a solid balance sheet and leveraging existing credit facilities to support operations and strategic growth investments. Investor confidence is maintained through consistent performance and clear execution of the business strategy.
balance sheet strength
지배구조 및 통제
Governance reflects standard public company practices with a professional, non-founder executive team.
복수의결권 주식: 아니오
주식 클래스 상세: Standard common equity
Integer Holdings operates with a professional Board of Directors, ensuring accountability. The governance structure is focused on minority shareholder alignment and board independence.
good governanceboard-led
건강 및 승계
No public concerns; succession was handled professionally.
건강 상태: no public concerns
승계 계획 공시: 예
핵심 인물 리스크: Low
Succession plan was well-communicated and executed.
succession planning
R&D 및 기술 비전
R&D efforts are tightly coupled with manufacturing process innovation.
Ongoing commitment to process and technological innovation within the CDMO space.
High focus on process-driven R&D to meet complex client requirements.
The R&D strategy is aimed at enhancing capabilities in manufacturing complex components and devices. Innovation is measured by its impact on client speed-to-market and cost reduction, rather than pure product development alone.
process innovationmanufacturing tech
인재 채용
Focuses on retaining top-tier regulatory and technical expertise.
Strong bench supported by clear succession and development plans.
유지율: strong
Khales prioritizes building a culture of excellence and accountability. He relies on internal talent development, as evidenced by his own promotion, and actively recruits industry experts to fill key regulatory and technical roles.
talent developmenttechnical expertise
강점
Deep operational knowledge of the medical manufacturing industry.
Operations: Extensive experience managing complex medical device production units.
operational excellenceindustry knowledge
약점 및 실패
Limited tenure as CEO makes him relatively untested in broad strategic pivots.
CEO Experience
Relatively short tenure; the market is currently evaluating his ability to lead beyond the initial transition.
untested
마케팅 및 브랜드
Brand perception remains anchored in technical reliability and manufacturing expertise.
Positioning as a premier partner in medical device contract manufacturing.
Marketing strategy is B2B-focused, emphasizing technical reliability, regulatory expertise, and speed-to-market for medical device customers. The brand is managed as a high-trust partner in the medical device value chain.
b2bbrand trust
PR 및 커뮤니케이션
Maintains a professional and low-profile public persona.
미디어 평판: low profile
Khales adopts a professional communication style, focusing on transparency with investors regarding the company's long-term strategy. He has maintained a smooth reputation transition from his predecessor, focusing on the continuity of corporate goals.
professionaltransparent
상류 / 하류 / 대체 기업